All Articles

Sintilimab Therapy in Patients with Previously Treated Advanced or Metastatic Gastric Cancer Demonstrates Modest Response

KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy.

Bavituximab Pembrolizumab Combination Demonstrates Antitumor Activity in Patients with Pretreated Advanced Gastric or Gastroesophageal Junction Cancer

Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile.

First-Line Toripalimab Combined with Chemotherapy Conveys Significant Benefits in Patients with Esophageal Squamous-Cell Carcinoma

Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer.

Progression-Free Survival Improved in Patients with HER2-Negative Recurrent or Advanced Gastric or Gastroesophageal Junction Cancer Receiving Nivolumab plus Chemotherapy

Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement.

PET/CT Imaging in Prostate Cancer Patients

Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer.

PSMA PET Imaging in Patients with Oligometastatic Prostate Cancer

PET/CT Imaging in Prostate Cancer Patients

Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer.

PYLARIFY and Next-Generation Imaging

By Neal D. Shore, MD

PET/CT Imaging in Prostate Cancer Patients

Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging.

PSMA-Targeted Imaging for Prostate Cancer Treatment

By Neal D. Shore, MD

Best Practices in GU Navigation

Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment.

A New Era of Treatment Options for Patients with Advanced Renal-Cell Cancer

By Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; Virginia Seery, CRNP, MSN